AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19706697 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (n = 16)
Number of subjects: 50
Study 19706697 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (n = 16)
Number of subjects: 50
Study 19706697 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 50
Study 19210631 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin (40 microg) administered i.v. over 30 min
Number of subjects: 10
Study 19210631 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo) administered i.v. over 30 min
Number of subjects: 10
Study 16770138 — intervention group
Group type: EXPERIMENTAL
Intervention: Dr. Brown's Natural Flow Baby Bottles
Number of subjects: 36
Study 16770138 — intervention group
Group type: COMPARATOR
Intervention: Placebo bottles
Number of subjects: 36
Study 12768356 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of 200 mg levodopa (LD)
Number of subjects: 2
Study 12768356 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous injection of 4 mg apomorphine (A)
Number of subjects: 2
Study 10770815 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scan before FOB (Group A)
Number of subjects: 171
Study 10770815 — intervention group
Group type: COMPARATOR
Intervention: FOB without prior CT scan (Group B)
Number of subjects: 171
Study 9327093 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone hydrochloride (NTX) 2 mg/kg
Number of subjects: 10
Study 9327093 — intervention group
Group type: COMPARATOR
Intervention: SIB episode
Number of subjects: 10
Study 8222031 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol anaesthesia with N2O (P/N2O)
Number of subjects: 75
Study 8222031 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol anaesthesia without N2O (P/O2)
Number of subjects: 75
Study 8222031 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone and halothane anaesthesia (T/H)
Number of subjects: 75
Study 3950252 — intervention group
Group type: EXPERIMENTAL
Intervention: Cat allergen treatment (15 with cat allergen)
Number of subjects: 41
Study 3950252 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 41
Study 3950252 — intervention group
Group type: COMPARATOR
Intervention: Dog allergen treatment (7 with dog allergen)
Number of subjects: 41
Study 30920245 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for seasonal affective disorder (CBT-SAD)
Number of subjects: 177
Study 30920245 — intervention group
Group type: COMPARATOR
Intervention: Light therapy
Number of subjects: 177
Study 29885168 — intervention group
Group type: EXPERIMENTAL
Intervention: Myrtus communis L. solution
Number of subjects: 90
Study 29885168 — intervention group
Group type: COMPARATOR
Intervention: Ketoconazole shampoo
Number of subjects: 90
Study 27103548 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention (2× weekly yoga classes for 12 weeks, complemented by regular home practice guided by a manual)
Number of subjects: 144
Study 27103548 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention
Number of subjects: 144
Study 27103548 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment group (control)
Number of subjects: 144
Study 24647274 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Advocate Crisis Plan (PACP)
Number of subjects: 212
Study 24647274 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-facilitated Crisis Plan (CCP)
Number of subjects: 212
Study 24647274 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 212
Study 22647089 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine ingestion (6 mg · kg⁻¹ body-mass)
Number of subjects: 0
Study 22647089 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20096897 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy food-containing diet with 10 g/d prebiotic (oligofructose-enriched inulin)
Number of subjects: 23
Study 20096897 — intervention group
Group type: COMPARATOR
Intervention: Prebiotic (10 g/d)
Number of subjects: 23
Study 20096897 — intervention group
Group type: COMPARATOR
Intervention: Soy food-containing diet (30 g/d soy protein, 61 mg/d isoflavones) with 10 g/d placebo (maltodextrin)
Number of subjects: 23
Study 18029465 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA supplementation (50 mg/d) plus exercise training (endurance and resistance)
Number of subjects: 31
Study 18029465 — intervention group
Group type: COMPARATOR
Intervention: Exercise training (endurance and resistance)
Number of subjects: 31
Study 15910512 — intervention group
Group type: EXPERIMENTAL
Intervention: AR-R15896AR 120 mg
Number of subjects: 15
Study 15910512 — intervention group
Group type: EXPERIMENTAL
Intervention: AR-R15896AR 350 mg
Number of subjects: 15
Study 15910512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 12095664 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate 40 mg
Number of subjects: 16
Study 12095664 — intervention group
Group type: COMPARATOR
Intervention: Atomoxetine 90 mg
Number of subjects: 16
Study 12095664 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate 20 mg and 40 mg
Number of subjects: 16
Study 12095664 — intervention group
Group type: COMPARATOR
Intervention: Atomoxetine 20 mg, 45 mg, and 90 mg
Number of subjects: 16
Study 12095664 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 16
Study 12144191 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve segmentectomy
Number of subjects: 8
Study 9875081 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg oestradiol treatment
Number of subjects: 19
Study 9875081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 7531378 — intervention group
Group type: EXPERIMENTAL
Intervention: Jejunal J-pouch after gastrectomy
Number of subjects: 0
Study 7531378 — intervention group
Group type: COMPARATOR
Intervention: Roux-en-Y pouch reconstruction
Number of subjects: 0
Study 2786009 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabumetone (2000 mg)
Number of subjects: 30
Study 2786009 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (3.6 g)
Number of subjects: 30
Study 2786009 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 2786009 — intervention group
Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 30
Study 31384899 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate implant placement
Number of subjects: 114
Study 31384899 — intervention group
Group type: COMPARATOR
Intervention: Delayed implant placement
Number of subjects: 114
Study 31384899 — intervention group
Group type: EXPERIMENTAL
Intervention: Flapless surgery
Number of subjects: 114
Study 31384899 — intervention group
Group type: EXPERIMENTAL
Intervention: SLA and DAE surface treatment methods
Number of subjects: 114
Study 31384899 — intervention group
Group type: EXPERIMENTAL
Intervention: Graft procedure
Number of subjects: 114
Study 28235974 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1
Number of subjects: 8
Study 28235974 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-19-36 amide
Number of subjects: 8
Study 28235974 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 8
Study 28235974 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 8
Study 26416653 — intervention group
Group type: EXPERIMENTAL
Intervention: simeprevir (SMV) in combination with pegylated interferon and ribavirin (PegIFN/R)
Number of subjects: 709
Study 26416653 — intervention group
Group type: COMPARATOR
Intervention: telapravir (TVR) in combination with pegylated interferon and ribavirin (PegIFN/R)
Number of subjects: 709
Study 24640205 — intervention group
Group type: EXPERIMENTAL
Intervention: Badriphal (Hippophae rhamnoides) 350 mg twice daily for 3 months
Number of subjects: 56
Study 24640205 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 56
Study 21194855 — intervention group
Group type: EXPERIMENTAL
Intervention: VLBW group
Number of subjects: 37
Study 21194855 — intervention group
Group type: COMPARATOR
Intervention: Normal group
Number of subjects: 37
Study 17852127 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label stimulant medication
Number of subjects: 36
Study 17852127 — intervention group
Group type: COMPARATOR
Intervention: Unmedicated children with ADHD
Number of subjects: 36
Study 16824073 — intervention group
Group type: EXPERIMENTAL
Intervention: CH100 (Chinese herbal therapy)
Number of subjects: 91
Study 16824073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 14616189 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine 24 mg/day
Number of subjects: 45
Study 14616189 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine 12 mg/day
Number of subjects: 45
Study 14616189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 14616189 — intervention group
Group type: EXPERIMENTAL
Intervention: Active medications (Tiagabine 12 mg/day and 24 mg/day)
Number of subjects: 45
Study 10853724 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up visits with extensive testing and resultant measures after one month
Number of subjects: 95
Study 10853724 — intervention group
Group type: COMPARATOR
Intervention: Control group (no follow-up visits)
Number of subjects: 95
Study 9193755 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytogenetic abnormalities detected at bone marrow harvest
Number of subjects: 190
Study 9193755 — intervention group
Group type: EXPERIMENTAL
Intervention: ABMT (Autologous Bone Marrow Transplantation)
Number of subjects: 190
Study 9193755 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional cytogenetic assessment
Number of subjects: 190
Study 8466422 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (E) - resistance and balance training, 12 weeks, 3 times per week.
Number of subjects: 31
Study 8466422 — intervention group
Group type: COMPARATOR
Intervention: Control group (C) - flexibility exercises performed sitting in a chair, 12 weeks, weekly meetings.
Number of subjects: 31
Study 31786776 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate
Number of subjects: 117900
Study 31786776 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycoproteins
Number of subjects: 117900
Study 31786776 — intervention group
Group type: EXPERIMENTAL
Intervention: LVLDLP
Number of subjects: 117900
Study 31786776 — intervention group
Group type: EXPERIMENTAL
Intervention: MVLDLC
Number of subjects: 117900
Study 31243035 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of an evidence-based, goal-directed checklist for potential organ donor maintenance
Number of subjects: 60
Study 31243035 — intervention group
Group type: COMPARATOR
Intervention: Usual care practices of the ICU
Number of subjects: 60
Study 28573669 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent GWG tracking among not-low-income women
Number of subjects: 898
Study 28573669 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent GWG tracking among low-income women
Number of subjects: 898
Study 26569501 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention (reorganization of care by trained chronic care coaches, reminder systems, structured follow‐up, patient self‐monitoring, decision‐support)
Number of subjects: 169
Study 26569501 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention
Number of subjects: 169
Study 26569501 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 169
Study 23838753 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA treatment
Number of subjects: 607
Study 23838753 — intervention group
Group type: EXPERIMENTAL
Intervention: ASPECTS M6 region interaction with age
Number of subjects: 607
Study 23838753 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentiform nucleus interaction with age
Number of subjects: 607
Study 23838753 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood sugar level interaction with age
Number of subjects: 607
Study 21207091 — intervention group
Group type: COMPARATOR
Intervention: EAC (esomeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 500 mg, all b.i.d. for 8 days)
Number of subjects: 62
Study 21207091 — intervention group
Group type: EXPERIMENTAL
Intervention: EACL (EAC plus Lactobacillus acidophilus, 5 × 10(9) organisms per capsule, 3 + 2 i.d. for 8 days)
Number of subjects: 62
Study 19327308 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation
Number of subjects: 75
Study 19327308 — intervention group
Group type: COMPARATOR
Intervention: Sham noninvasive ventilation (Control)
Number of subjects: 75
Study 16963045 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler ultrasound of the uterine arteries
Number of subjects: 433
Study 16963045 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorimetric immunoassays for free beta‐hCG and PAPP‐A
Number of subjects: 433
Study 15577587 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-injection transmission-based segmented attenuation correction (SAC) technique
Number of subjects: 10
Study 15577587 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmissionless calculated attenuation correction (CAC) technique
Number of subjects: 10
Study 11323731 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine (45mg)
Number of subjects: 10
Study 11323731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 9337763 — intervention group
Group type: EXPERIMENTAL
Intervention: Angioplasty
Number of subjects: 0
Study 9337763 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass surgery
Number of subjects: 0
Study 9337763 — intervention group
Group type: COMPARATOR
Intervention: Angioplasty and Coronary artery bypass surgery
Number of subjects: 0
Study 7943831 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 5 micrograms.kg-1
Number of subjects: 57
Study 7943831 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 2.5 micrograms.kg-1
Number of subjects: 57
Study 7943831 — intervention group
Group type: COMPARATOR
Intervention: Control (famotidine alone)
Number of subjects: 57
Study 7943831 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (both doses)
Number of subjects: 57
Study 7943831 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 57
Study 3034841 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus misonidazole
Number of subjects: 117
Study 3034841 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 117
Study 29731344 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline LCS score
Number of subjects: 327
Study 29731344 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom improvement (increase in LCS of two points or more during treatment)
Number of subjects: 327
Study 26630942 — intervention group
Group type: EXPERIMENTAL
Intervention: Limb Remote Ischemic Conditioning (RIC) - four lower-limb conditioning sessions consisting of four 5-min cycles per session over nonconsecutive days.
Number of subjects: 82
Study 26630942 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched controls with aSAH).
Number of subjects: 82
Study 24512953 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI
Number of subjects: 146
Study 24512953 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI plus cetuximab
Number of subjects: 146
Study 23464930 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose SPAA (5/10 or 10/10 mg)
Number of subjects: 1461
Study 23464930 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 1461
Study 20010119 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirulina (6 g x d(‐1))
Number of subjects: 9
Study 20010119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 17982749 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AE) program
Number of subjects: 30
Study 17982749 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthening exercise (SE) program
Number of subjects: 30
Study 16860045 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate (DMPA) 150 mg/mL
Number of subjects: 608
Study 16860045 — intervention group
Group type: COMPARATOR
Intervention: Nonhormonal contraception
Number of subjects: 608
Study 14624371 — intervention group
Group type: EXPERIMENTAL
Intervention: CCR5-wt/Delta32 genotype
Number of subjects: 1049
Study 14624371 — intervention group
Group type: EXPERIMENTAL
Intervention: CCR5-wt/wt genotype with CCR5-59029-A/A variant
Number of subjects: 1049
Study 14624371 — intervention group
Group type: EXPERIMENTAL
Intervention: SDF1-3'-A/A variant
Number of subjects: 1049
Study 14624371 — intervention group
Group type: EXPERIMENTAL
Intervention: CCR5-59353, CCR5-59356, or CCR2 genotypes
Number of subjects: 1049
Study 10760343 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 10
Study 10760343 — intervention group
Group type: COMPARATOR
Intervention: Nonexercise Control
Number of subjects: 10
Study 9010008 — intervention group
Group type: EXPERIMENTAL
Intervention: Suramin administered intravenously in escalating dosages (300, 350, and 400 micrograms ml-1)
Number of subjects: 22
Study 9010008 — intervention group
Group type: EXPERIMENTAL
Intervention: Suramin administered intravenously in escalating dosages (350 and 400 micrograms ml-1)
Number of subjects: 22
Study 9010008 — intervention group
Group type: EXPERIMENTAL
Intervention: Suramin administered intravenously with neurological monitoring
Number of subjects: 22
Study 9010008 — intervention group
Group type: EXPERIMENTAL
Intervention: Suramin with drug discontinuation and plasmapheresis
Number of subjects: 22
Study 1509986 — intervention group
Group type: EXPERIMENTAL
Intervention: AM3 (glycophosphopeptide), 1 g daily for 4 months
Number of subjects: 20
Study 1509986 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 20
Study 6747061 — intervention group
Group type: COMPARATOR
Intervention: Diet
Number of subjects: 53
Study 6747061 — intervention group
Group type: COMPARATOR
Intervention: Diet plus exercise
Number of subjects: 53
Study 6747061 — intervention group
Group type: COMPARATOR
Intervention: No treatment control
Number of subjects: 53
Study 30292481 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocktail of 12 natural lytic anti‐Pseudomonas aeruginosa bacteriophages (PP1131; 1 × 106 PFU/mL) applied as a daily topical treatment for 7 days.
Number of subjects: 27
Study 30292481 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (1% sulfadiazine silver emulsion cream) applied as a daily topical treatment for 7 days.
Number of subjects: 27
Study 30292481 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocktail of 12 natural lytic anti‐Pseudomonas aeruginosa bacteriophages (PP1131).
Number of subjects: 27
Study 30292481 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (1% sulfadiazine silver emulsion cream).
Number of subjects: 27
Study 27739232 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous infusion of 120 mg of ketorolac tromethamine over 24 hours
Number of subjects: 12
Study 27739232 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular bolus injections of 30 mg of ketorolac tromethamine every 6 hours (total daily dose of 120 mg)
Number of subjects: 12
Study 26770927 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E therapy (n=58)
Number of subjects: 335
Study 26770927 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=58)
Number of subjects: 335
Study 25127231 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurostimulation (frequency 180 Hz; pulse width 120 μs; amplitude 0.5 V below adverse event threshold)
Number of subjects: 62
Study 25127231 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (amplitude 0 V)
Number of subjects: 62
Study 22489807 — intervention group
Group type: EXPERIMENTAL
Intervention: Active low-frequency electrical stimulation (2/100 Hz)
Number of subjects: 62
Study 22489807 — intervention group
Group type: COMPARATOR
Intervention: Sham (placebo) treatment
Number of subjects: 62
Study 19156629 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 0
Study 19156629 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 0
Study 17592702 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-made orthoses
Number of subjects: 178
Study 17592702 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready-made orthoses
Number of subjects: 178
Study 17592702 — intervention group
Group type: COMPARATOR
Intervention: Control group (no orthoses)
Number of subjects: 178
Study 12765737 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 0
Study 12765737 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 0
Study 12765737 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11251350 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended out‐of‐hospital prophylaxis with low‐molecular‐weight heparin
Number of subjects: 0
Study 11251350 — intervention group
Group type: COMPARATOR
Intervention: A2 recommendation for extended prophylaxis
Number of subjects: 0
Study 9299666 — intervention group
Group type: EXPERIMENTAL
Intervention: Favre system
Number of subjects: 14
Study 8348279 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg methylprednisolone and lignocaine
Number of subjects: 55
Study 8348279 — intervention group
Group type: COMPARATOR
Intervention: Lignocaine alone
Number of subjects: 55
Study 3034021 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg ramipril
Number of subjects: 160
Study 3034021 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg ramipril
Number of subjects: 160
Study 3034021 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg ramipril
Number of subjects: 160
Study 3034021 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of ramipril
Number of subjects: 160
Study 3034021 — intervention group
Group type: COMPARATOR
Intervention: Placebo (washout phase)
Number of subjects: 160
Study 30350406 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated intervention combining health systems navigation and psychosocial counselling for early engagement of antiretroviral therapy (ART) and substance use treatment for PWID living with HIV.
Number of subjects: 1154
Study 27793141 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component, school-based, physical activity intervention
Number of subjects: 3124
Study 25891551 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline T2 lesion volume
Number of subjects: 43